Get the Stockscreener App
3.06
3.03%
0.09
Pre-market:
3.06
Why is Abcellera Biologics Inc (ABCL) Stock down?
We've noticed a 7.67% decline in Abcellera Biologics Inc (ABCL) stock during the 2025-01-14 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
27 Jun, 2023:
Shares of AbCellera Biologics (ABCL) fell down 8.10% today. In fact, BACL stock trades down 88% off from its highs record at its initial public offering (IPO) in late 2020. AbCellera Biologics's revenue generation has gone down in 2023 because the emergency-use authorization from the U.S. Food and Drug Administration (FDA) on a partnered COVID-19 treatment, bentelovimab, expired in 2022.
https://ca.finance.yahoo.com/news/canadian-biotech-stocks-quietly-changing-224500362.html
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):